Microtubule Inhibitor

Breast Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="s47"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. The chemical name for ixabepilone is (1 S,3 S,7 S,10 R,11 S,12 S,16 R)-7,11 -dihydroxy-8,8,10,12,16-pentamethyl-3- [(1 E)-1 -methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0] heptadecane-5,9-dione, and it has a molecular weight of 506.7. Ixabepilone has the following structural formula: <img alt="Structural Formula
" src="ixe00-0000-01.jpg"/>IXEMPRA (ixabepilone) for injection is intended for intravenous infusion only after constitution with the supplied DILUENT and after further dilution with a specified infusion fluid [see dosage ( <a href="#s14">2.</a>)]. IXEMPRA (ixabepilone) for injection is supplied as a sterile, non-pyrogenic, single-dose vial providing 15 mg or 45 mg ixabepilone as a lyophilized white powder. The DILUENT for IXEMPRA is a sterile, non-pyrogenic, solution of 52.8% (w/v) purified polyoxyethylated castor oil and 39.8% (w/v) dehydrated alcohol, USP. The IXEMPRA (ixabepilone) for injection and the DILUENT for IXEMPRA are copackaged and supplied as IXEMPRA Kit</section>

IXEMPRA

ixabepilone 45 MG Injection

ixabepilone 45 MG Injection [IXEMPRA]

ixabepilone 15 MG Injection

ixabepilone 15 MG Injection [IXEMPRA]

ixabepilone

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

Ixempra Enrollment Form 

Patient Authorization Form 

Patient Authorization Form - Spanish 

Enroll in Patient Savings Progam 

Other HCP Resources 

Patient Resources 

Patient Brochure 

Patient Brochure - Spanish

Side Effects Tracker

Instructions For Use: Metastatic Breast Cancer 

Coverage Authorization Request 

Coverage Authorization Appeals